کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5558183 | 1561080 | 2017 | 6 صفحه PDF | دانلود رایگان |
BackgroundThe baseline exercise capacity evaluated by cardiopulmonary exercise testing (CPET) and the change after administration of calcium channel blockers (CCB) therapy in patients with vasodilator-responsive idiopathic pulmonary arterial hypertension (VR-IPAH)are unknown.Methods25 patients with newly diagnosed VR-IPAH from 1 January 2012 to 16 November 2015 were prospectively enrolled, and 28 age, sex and pulmonary vascular resistance matched newly diagnosed patients with vasodilator-nonresponsive idiopathic pulmonary arterial hypertension (VNR-IPAH) were enrolled. CPET was performed before and after 3.5 ± 0.8 months of CCB or sildenafil therapy.ResultsVentilatory efficiency at rest, anaerobic threshold (AT), and peak were significantly higher (lower in VËE/VËCO2@AT and higher in PETCO2@AT) in VR-IPAH group than that in VNR-IPAH group. Peak VËO2 (13.9 ± 2.9 mL kgâ1·minâ1 vs 16.4 ± 4.1 mL kgâ1·minâ1, p = 0.001), peak O2 pulse (5.5 ± 0.8 mL minâ1·beatâ1 vs 6.9 ± 1.3 mL minâ1·beatâ1, p = 0.001), VËE/VËCO2@AT (34.2 ± 5.0 vs 31.6 ± 3.1, p = 0.02) and PETCO2@AT (33.1 ± 4.0 mmHg vs 35.3 ± 3.2 mmHg, p = 0.02) were significantly improved after high dose of CCB therapy, along with improvement of WHO functional class, 6-min walking distance, NT-proBNP and tricuspid regurgitation pressure gradient.ConclusionsVentilatory efficiency in patients with VR-IPAH is better than that in patients with VNR-IPAH. CCB can improve aerobic capacity and ventilatory efficiency during exercise in patients with VR-IPAH.Clinical trial registration number: ClinicalTrials.gov:NCT02061787.
Journal: Pulmonary Pharmacology & Therapeutics - Volume 43, April 2017, Pages 26-31